Literature DB >> 1366622

RNA enzymes (ribozymes) as antiviral therapeutic agents.

J J Rossi1, N Sarver.   

Abstract

Among the landmark discoveries of recent years are ribozymes, RNA molecules which possess enzymatic, self-cleaving activities. The concept of exploiting the ribozyme catalytic center for cleaving (inactivating) a specific RNA transcript is now emerging as a potential therapeutic or preventative strategy in human diseases, veterinary medicine and agriculture. Linked to the catalytic center of the ribozyme are RNA sequences which are complementary to, and thus serve to target the ribozyme to, a unique RNA sequence. Specific association of the ribozyme with its target via base pairing, cleavage of the RNA substrate and subsequent recycling of the ribozyme make these catalytic RNA molecules attractive as antiviral agents. Theoretically, ribozymes can be adapted for the destruction of any RNA species, whatever its origin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1366622     DOI: 10.1016/0167-7799(90)90169-x

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  15 in total

1.  Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells.

Authors:  T Kuwabara; M Warashina; S Koseki; M Sano; J Ohkawa; K Nakayama; K Taira
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

2.  Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo.

Authors:  N R Taylor; B E Kaplan; P Swiderski; H Li; J J Rossi
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

3.  Assaying synthetic ribozymes in plants: high-level expression of a functional hammerhead structure fails to inhibit target gene activity in transiently transformed protoplasts.

Authors:  L Mazzolini; M Axelos; N Lescure; P Yot
Journal:  Plant Mol Biol       Date:  1992-11       Impact factor: 4.076

Review 4.  Convergent evolution of twintron-like configurations: One is never enough.

Authors:  Mohamed Hafez; Georg Hausner
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

5.  Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better.

Authors:  D Herschlag
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

6.  Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III.

Authors:  S Koseki; T Tanabe; K Tani; S Asano; T Shioda; Y Nagai; T Shimada; J Ohkawa; K Taira
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 7.  Antiviral ribozymes. New jobs for ancient molecules.

Authors:  A Menke; G Hobom
Journal:  Mol Biotechnol       Date:  1997-08       Impact factor: 2.695

Review 8.  Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.

Authors:  Jiehua Zhou; John Rossi
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

9.  A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.

Authors:  O Yamada; G Kraus; L Luznik; M Yu; F Wong-Staal
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

10.  An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield.

Authors:  Z Xing; J L Whitton
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.